322 related articles for article (PubMed ID: 30503851)
1. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
Olson B; Patnaik A
Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
3. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
4. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Jansen CS; Prokhnevska N; Kissick HT
Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
[TBL] [Abstract][Full Text] [Related]
5. Revisiting Immunotherapy: A Focus on Prostate Cancer.
Cha HR; Lee JH; Ponnazhagan S
Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
[TBL] [Abstract][Full Text] [Related]
6. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Bou-Dargham MJ; Sha L; Sang QA; Zhang J
BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
[TBL] [Abstract][Full Text] [Related]
7. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
8. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract][Full Text] [Related]
10. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
Miyahira AK; Kissick HT; Bishop JL; Takeda DY; Barbieri CE; Simons JW; Pienta KJ; Soule HR
Prostate; 2015 Mar; 75(4):337-47. PubMed ID: 25358693
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
12. Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models.
Kronik N; Kogan Y; Elishmereni M; Halevi-Tobias K; Vuk-Pavlović S; Agur Z
PLoS One; 2010 Dec; 5(12):e15482. PubMed ID: 21151630
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Dolcetti R; De Re V; Canzonieri V
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29844297
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW; Bryant RJ; Parkes EE
Endocr Relat Cancer; 2021 Jul; 28(8):T95-T107. PubMed ID: 34128831
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
16. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity.
Corapi E; Carrizo G; Compagno D; Laderach D
Front Immunol; 2018; 9():2190. PubMed ID: 30319642
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A; Sepe P; Beninato T; Claps M; Guadalupi V; Verzoni E; Giannatempo P; Baciarello G; de Braud F; Procopio G
Per Med; 2022 Jan; 19(1):51-66. PubMed ID: 34873959
[TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Immunotherapy-Finally in From the Cold?
Runcie KD; Dallos MC
Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for prostate cancer.
Karnes RJ; Whelan CM; Kwon ED
Curr Pharm Des; 2006; 12(7):807-17. PubMed ID: 16515497
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
